Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.46 |
| ▸ | HTR3B | O95264 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158555 | 0.97 | NPSR1 (0.51) | GAANPSR1HTR3EHTR3BHTR3A | |
| SCHEMBL4150707 | 0.93 | HTR3E (0.49) | GAANPSR1HTR3EHTR3BHTR3A | |
| SCHEMBL4163322 | 0.80 | L3MBTL1 (0.41) | GAANPC1RAB9AKMT2A | |
| SCHEMBL4154113 | 0.79 | HPGD (0.43) | GAAKMT2A | |
| SCHEMBL4159720 | 0.76 | NPC1 (0.41) | GAANPSR1NPC1RAB9AKMT2A | |
| SCHEMBL4173665 | 0.75 | HPGD (0.46) | GAANPC1RAB9A | |
| SCHEMBL3184732 | 0.74 | HPGD (0.49) | GAANPC1RAB9A | |
| SCHEMBL1515207 | 0.72 | HTR3E (0.66) | GAANPSR1HTR3EHTR3BHTR3A | |
| SCHEMBL4159489 | 0.71 | AKR1C3 (0.41) | GAANPC1RAB9ANOTUMKMT2A | |
| SCHEMBL4152944 | 0.70 | P2RX7 (0.42) | GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | ALVARO GIUSEPPE | 2009-07-30 | — | — | US | disclosed |
| US-20070073061-A1 | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1622871-A1 | CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004099143-A1 | CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLAXO GROUP LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070073061-A1 | Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them | SLC6A4, OPRL1, HCRTR1 | GAA 4764/4885NPSR1 23/4885HTR3E 106/4885 |
| US-20090192194-A1 | Cyclic Amine Derivatives, Processes For Their Preparation, And Pharmaceutical Compositions Containing Them | SLC6A4, OPRL1, HCRTR1 | GAA 4764/4885NPSR1 23/4885HTR3E 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.